Exela Drug Patent Portfolio
Exela owns 2 orange book drugs protected by 17 US patents Given below is the list of Exela's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10478453 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10583155 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10653719 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10905713 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10905714 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10912795 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10918662 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10933089 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11510941 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11510942 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11642370 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11648262 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11679125 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11684636 | Stable, highly pure l-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11826383 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11969439 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US9486530 | Ganciclovir compositions and related methods | 02 Sep, 2034 | Active |
Latest Legal Activities on Exela's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Exela.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent eCertificate of Correction | 10 Dec, 2024 | US11969439 |
| Mail Patent eCofC Notification | 10 Dec, 2024 | US11969439 |
| Patent eCofC Notification | 10 Dec, 2024 | US11969439 |
| Email Notification | 10 Dec, 2024 | US11969439 |
| Post Issue Communication - Certificate of Correction | 21 Nov, 2024 | US11969439 |
| Recordation of Patent eCertificate of Correction | 19 Nov, 2024 | US10918662 |
| Patent eCofC Notification | 19 Nov, 2024 | US10918662 |
| Email Notification | 19 Nov, 2024 | US10918662 |
| Mail Patent eCofC Notification | 19 Nov, 2024 | US10918662 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 08 Nov, 2024 | US9486530 |
| 7.5 yr surcharge - late pmt w/in 6 mo, Small Entity | 08 Nov, 2024 | US9486530 |
| Post Issue Communication - Certificate of Correction | 29 Oct, 2024 | US10918662 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 12 Aug, 2024 | US10933089 |
| Request for Trial Denied | 08 Aug, 2024 | US11642370 |
| Email Notification | 23 Jul, 2024 | US11826383 |
Exela's Drug Patent Litigations
Exela's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 19, 2020, against patent number US10478453. The petitioner Eton Pharmaceuticals, Inc., challenged the validity of this patent, with Exela Pharma Sciences, LLC as the respondent. Click below to track the latest information on how companies are challenging Exela's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11642370 | February, 2024 |
Institution Denied
(08 Aug, 2024)
| Exela Pharma Sciences, LLC | Nexus Pharmaceuticals LLC |
| US10653719 | September, 2020 |
Institution Denied
(23 Apr, 2021)
| Exela Pharma Sciences LLC | Eton Pharmaceuticals, Inc. |
| US10583155 | June, 2020 |
Institution Denied
(15 Dec, 2020)
| Exela Pharma Sciences, LLC | Eton Pharmaceuticals Inc. |
| US10478453 | May, 2020 |
Institution Denied
(18 Nov, 2020)
| Exela Pharma Sciences, LLC | Eton Pharmaceuticals, Inc. |
Exela's Family Patents
Exela Drug List
Given below is the complete list of Exela's drugs and the patents protecting them.
1. Elcys
Elcys is protected by 16 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10478453 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(12 years from now)
| Active |
| US10583155 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(12 years from now)
| Active |
| US10653719 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(12 years from now)
| Active |
| US10905713 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(12 years from now)
| Active |
| US10905714 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(12 years from now)
| Active |
| US10912795 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(12 years from now)
| Active |
| US10918662 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(12 years from now)
| Active |
| US10933089 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(12 years from now)
| Active |
| US11510941 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(12 years from now)
| Active |
| US11510942 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(12 years from now)
| Active |
| US11642370 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(12 years from now)
| Active |
| US11648262 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(12 years from now)
| Active |
| US11679125 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(12 years from now)
| Active |
| US11684636 | Stable, highly pure l-cysteine compositions for injection and methods of use |
15 Jan, 2039
(12 years from now)
| Active |
| US11826383 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(12 years from now)
| Active |
| US11969439 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(12 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Elcys's drug page
2. Ganzyk-rtu
Ganzyk-rtu is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9486530 | Ganciclovir compositions and related methods |
02 Sep, 2034
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ganzyk-rtu's drug page